Brief: SyntheticMR's feature REMyDI is now CE-marked for clinical use in Europe

Syntheticmr publ AB

19/04/2017 12:02

April 19 - SYNTHETICMR AB  SYNTH.ST : 
    * ANNOUNCED ON TUESDAY THAT ITS FEATURE REMYDI IS NOW 
CE-MARKED FOR CLINICAL USE IN EUROPE 
    * REMYDI PROVIDES AUTOMATIC MEASUREMENT OF MYELIN VOLUME IN 
THE BRAIN 
    * REMYDI IS NOW AVAILABLE IN THE SYMRI NEURO REMYDI PACKAGE 
    * SYMRI IS A CE-MARKED PRODUCT AND IS FDA 510(K) PENDING 
 
     
 Source text: http://bit.ly/2pfRuSr 
     
 Further company coverage:  SYNTH.ST   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))